Register to receive a free U.S. Market for Urological Devices report synopsis and brochure

Cogentix Medical, Inc., a global medical device company focused on providing the Urology, Uro/Gyn and Gynecology markets with innovative and proprietary products, recently announced a $2 million investment in Vensica Medical. Vensica is a privately-held Israeli-based company developing VensiCare, an ultrasound based, needle-free drug delivery system. The initial indication pursued for the VensiCare device will be the delivery of botulinum toxin (such as Botox® or Dysport®) to treat overactive bladder (OAB). Vensica also has intellectual property for the delivery of oncology agents to the bladder. Vensica currently anticipates commencing human clinical trials of VensiCare for OAB during the fourth quarter of 2018. Cogentix will receive one seat on the Vensica Board and options to acquire the entire company for an additional $8 million.

“We are very excited about the potential the VensiCare product may provide for the more than 42 million patients in the US suffering from overactive bladder and its symptoms. The ability to offer another minimally invasive treatment option and significantly increase the number of patients who receive a 3rd line therapy for OAB is truly an exciting opportunity to leverage our strong urology market presence. Our physician customers often use Botox for the treatment of overactive bladder, and we believe Vensica’s approach and product pathway currently show promise for revolutionizing the manner in which botulinum toxin is administered for OAB,” said Darin Hammers, President and CEO. “This is our third business development transaction in the last three months and demonstrates our team’s commitment to prudently investing the cash on our balance sheet in a variety of transactions that now include acquisition, licensing and development agreements.”

“We are thrilled to partner with Cogentix as we continue the development of VensiCare,” said Avner Geva, CEO of Vensica. “We believe that Cogentix is the most attractive partner for Vensica given their knowledge of the OAB market and their successful track record with Urgent PC. We are confident this partnership will result in maximizing the potential of VensiCare.”

“The structure of this investment allows Cogentix to oversee the development of the high potential VensiCare device for a modest initial investment,” continued Mr. Hammers. “Further, the agreement gives the Company the option to acquire all of Vensica at a fixed price if significant value creating milestones are achieved. And while the initial work of Vensica focuses on the delivery of botulinum toxin to treat OAB, we believe the VensiCare product has the potential to be a broad based drug delivery platform that could deliver a variety of drugs for other indications, such as cancer.”

For Further Information

The report covers the U.S. as a whole, as well as market segments for urinary incontinence devices, stone management devices, BPH treatment devices, urological endoscopes, prostate cancer treatment devices, urodynamic equipment, and nephrostomy devices. The iData series on the market for urological devices also covers the U.S., India, China, Japan, and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.